Deferiprone.
| Characteristics | |
| Route of administration | PO |
| Half-life | 2 to 3 hours |
| Primary route of iron excretion | Urine |
| Dose range | 50–100 mg/kg/d |
| Guidelines for Monitoring Therapy | |
| CBC with differential weekly | |
| ALT level monthly for first 3–6 months, then every 6 months | |
| Serum ferritin level quarterly | |
| Assessment of liver iron annually | |
| Assessment of cardiac iron annually after 10 years of age | |
| Advantages | |
| Orally active | |
| Safety profile well established | |
| Enhanced removal of cardiac iron | |
| May be combined with deferoxamine | |
| Disadvantages | |
| May not achieve negative iron balance in all patients at 75 mg/kg/day | |
| Risk of agranulocytosis and need for weekly blood counts | |
| Characteristics | |
| Route of administration | PO |
| Half-life | 2 to 3 hours |
| Primary route of iron excretion | Urine |
| Dose range | 50–100 mg/kg/d |
| Guidelines for Monitoring Therapy | |
| CBC with differential weekly | |
| ALT level monthly for first 3–6 months, then every 6 months | |
| Serum ferritin level quarterly | |
| Assessment of liver iron annually | |
| Assessment of cardiac iron annually after 10 years of age | |
| Advantages | |
| Orally active | |
| Safety profile well established | |
| Enhanced removal of cardiac iron | |
| May be combined with deferoxamine | |
| Disadvantages | |
| May not achieve negative iron balance in all patients at 75 mg/kg/day | |
| Risk of agranulocytosis and need for weekly blood counts | |